Assessing heart function in patients with liver cirrhosis undergoing TIPSS placement

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the development of cardiac decompensation in patients with decompensated liver cirrhosis who are undergoing transjugular intrahepatic portosystemic shunt (TIPSS) implantation. Participants will undergo cardiac magnetic resonance imaging (MRI) and echocardiographic examinations at various intervals before and after the procedure, along with laboratory tests to monitor specific markers. The study aims to identify the frequency of cardiac symptoms and associated changes over a one-year period, which could inform future treatment protocols and patient selection criteria for TIPSS. By closely monitoring these patients, the research seeks to enhance understanding of the cardiac implications of liver cirrhosis and TIPSS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 99 years
* Written informed consent of the patient
* Decompensated liver cirrhosis, defined by clinical, imaging or laboratory criteria
* Patient receives an elective TIPSS in the appropriate clinical context at the JUH

Exclusion Criteria:

* Pregnancy
* Implants not suitable for magnetic resonance imaging
* Medical/personal reasons against magnetic resonance imaging (claustrophobia, patient cannot lie flat or follow breathing commands)
* Patient in critical condition or incompliant

Where it's running

• Jena University Hospital
  Jena, Thuringia, Germany Recruiting

Study contacts

• Principal investigator: Stephanie Gräger — Jena University Hospital
• Study coordinator: Stephanie Gräger
• Email: stephanie.graeger@med.uni-jena.de
• Phone: +4936419324800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD

  This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.

  Recruiting National University Health System, Singapore · Singapore, Singapore · NCT07861191

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS

  This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.

  Recruiting Early Phase 1 Air Force Military Medical University, China · Xi'an · NCT07683936

• Peanut intake and liver health in adults with MASLD

  This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT07646197

• Guided electronic tools to help clinicians manage MASLD

  Aimed at testing whether an electronic decision support tool used in primary care and specialty settings can help clinicians better manage MASLD in adults.

  Recruiting Vanderbilt University Medical Center · Nashville, Tennessee · NCT07382349

• Liver gene response to IV glucose during bariatric surgery in obese people with and without MASLD.

  This trial will test whether giving sugar through a vein changes liver gene activity during bariatric surgery in people with obesity who do or do not have MASLD.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT07326865

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.